Teva Pharma (TEVA) Tops Q2 EPS by 2c, Affirms Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
Teva Reports Second Quarter 2020 Financial Results
August 5, 2020 7:00 AM EDTRevenues of $3.9 billion GAAP diluted EPS of $0.13 Non-GAAP diluted EPS of $0.55 Free cash flow of $582 million Full year 2020 business outlook reaffirmed: Net revenues of $16.6 - $17 billion EBITDA of $4.5 - $4.9 billion EPS of $2.30 - $2.55 Free cash flow of $1.8 - $2.2 billion
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended June 30, 2020.
This press release features multimedia. View the full... More
